Marketed Drugs Oncology

OncologyDrug News

Oncology Jobs

Find an open position today!

Nexavar on the Chinese market

The State Food and Drug Administration (SFDA) of China approved Nexavar (sorafenib) tablets for the treatment of liver cancer patients. by Pierre-Philippe Luyet, PhD , 29/07/2008

Nexavar (sorafenib) Phase III Trial stopped

by Fabio Ferfoglia, PhD , 25/02/2008




SelectedRegional Oncology Drug Revenues (milion USD)
BEVACIZUMAB6018.54ROCHE HOLDING LTD2009, Worldwide
TRASTUZUMAB5093.8ROCHE HOLDING LTD2009, Worldwide
IMATINIB MESYLATE3944.0NOVARTIS AG2009, Worldwide
DOCETAXEL3113.11SANOFI-AVENTIS2009, Worldwide
IMATINIB MESYLATE2856.0NOVARTIS AG2009, Rest Of The World
DOCETAXEL1930.5SANOFI-AVENTIS2009, Rest Of The World
ANASTROZOLE1921.0ZENECA GROUP PLC2009, Worldwide
ANASTROZOLEJun 28, 2010TEVA PHARMACEUTICAL INDUSTRIES LTD
OXALIPLATINJun 2, 2010FRESENIUS BIOTECH
BICALUTAMIDEMay 13, 2010FRESENIUS KABI
EPIRUBICIN HYDROCHLORIDEMar 25, 2010X-GEN PHARMACEUTICALS INC
TEMOZOLOMIDEMar 1, 2010BARR PHARMACEUTICALS INC
PACLITAXELDec 9, 2009ACTAVIS GROUP